The Developmental and Translational Study on Biomarkers and Clinical Characteristics-based Diagnostic and Therapeutic Identification of Major Depressive Disorder: Study Protocol for a Multicenter Randomized Controlled Trial in China

Xiaohua Liu, Yun Wang, Daihui Peng, Huifeng Zhang, Yanqun Zheng, Yan Wu, Yun-Ai Su, Ming Liu, Xiancang Ma, Yi Li, Jianfei Shi, Xiaojing Cheng, Han Rong, Yiru Fang, Xiaohua Liu, Yun Wang, Daihui Peng, Huifeng Zhang, Yanqun Zheng, Yan Wu, Yun-Ai Su, Ming Liu, Xiancang Ma, Yi Li, Jianfei Shi, Xiaojing Cheng, Han Rong, Yiru Fang

Abstract

Background: Major depressive disorder (MDD) is a heterogeneous mental disease that encompasses different subtypes and specifiers. Clinically targeted treatments have not been identified yet, although standardized strategies are recommended by several clinical guidelines. The main aim of this study is to respectively identify the precise treatment for three different subtypes of MDD (ie, melancholic, atypical, and anxious).

Methods: An 8-to-12-week, multicenter randomized controlled trial (RCT) with a parallel group design will be conducted to determine the most effective and appropriate treatment. A total of 750 adults diagnosed with MDD will be recruited, categorized into melancholic, atypical or anxious type based on the assessment of the Inventory of Depressive Symptomatology (IDS30) and the Hamilton Anxiety Scale (HAMA), and 1:1 randomly assigned to different intervention groups. Blood draw, EEG test, and MRI scan will be performed at baseline and endpoint. Clinical symptom and side-effects will be evaluated at critical decision points (CDP) including weeks two, four, six, eight, and 12 after treatment. The primary outcome is total score and reduction rate of the 17-Hamilton Depression Rating Scale (17-HDRS). The secondary outcomes include the scores of the Quick Inventory of Depressive Symptomatology-self-report (QIDS-SR), IDS30, HAMA and the Treatment Emergent Symptom Scale (TESS). All the data will be analyzed by SAS software.

Discussion: The study commenced recruitment in August 2017 and is currently ongoing.

Trial registration: ClinicalTrials.gov Identifier: NCT03219008 (July 17, 2017).

Keywords: MDD; RCT; antidepressant; cCBT; computerized cognitive behavioral treatment; major depressive disorder; physical therapy; randomized controlled trial; subtype.

Conflict of interest statement

The authors declare that they have no conflict of interests in this work.

© 2020 Liu et al.

Figures

Figure 1
Figure 1
The criteria for different subtypes of MDD.
Figure 2
Figure 2
Standard protocol items— recommendations for interventional trials (SPIRIT).
Figure 3
Figure 3
Flow of participants through the study.

References

    1. Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317(15):1517. doi:10.1001/jama.2017.3826
    1. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry. 2013;12(2):137–148. doi:10.1002/wps.20038
    1. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56–67. doi:10.1002/wps.20089
    1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. doi:10.1176/appi.ajp.163.1.28
    1. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119–142. doi:10.1016/S0197-2456(03)00112-0
    1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi:10.1176/ajp.2006.163.11.1905
    1. Arnow BA, Blasey C, Williams LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatry. 2015;172(8):743–750. doi:10.1176/appi.ajp.2015.14020181
    1. McGrath PJ, Khan AY, Trivedi MH, et al. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry. 2008;69(12):1847–1855. doi:10.4088/jcp.v69n1201
    1. Uher R, Dernovsek MZ, Mors O, et al. Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J Affect Disord. 2011;132(1–2):112–120. doi:10.1016/j.jad.2011.02.014
    1. Bobo WV, Chen H, Trivedi MH, et al. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord. 2011;133(3):467–476. doi:10.1016/j.jad.2011.04.032
    1. Xu K, Jiang W, Ren L, et al. Impaired interhemispheric connectivity in medication-naive patients with major depressive disorder. J Psychiatry Neurosci. 2013;38(1):43–48. doi:10.1503/jpn.110132
    1. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342–351. doi:10.1176/appi.ajp.2007.06111868
    1. Braund TA, Palmer DM, Williams LM, Harris AW. Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: an iSPOT-D report. Aust N Z J Psychiatry. 2019;53(8):782–793. doi:10.1177/0004867419835933
    1. Gili M, Roca M, Armengol S, Asensio D, Garcia-Campayo J, Parker G. Clinical patterns and treatment outcome in patients with melancholic, atypical and non-melancholic depressions. PLoS One. 2012;7(10):e48200. doi:10.1371/journal.pone.0048200
    1. Stewart JW, McGrath PJ, Fava M, et al. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol. 2010;13(1):15–30. doi:10.1017/S1461145709000182
    1. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Rae AM. A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand. 2003;108(1):20–23. doi:10.1034/j.1600-0447.2003.00120.x
    1. Lin CH, Huang CJ, Liu SK. Melancholic features in inpatients with major depressive disorder associate with differential clinical characteristics and treatment outcomes. Psychiatry Res. 2016;238:368–373. doi:10.1016/j.psychres.2015.11.009
    1. Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(6):865–873. doi:10.4088/jcp.v67n0602
    1. Pae CU, Lim HK, Han C, et al. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. Expert Rev Neurother. 2007;7(10):1251–1263. doi:10.1586/14737175.7.10.1251
    1. Herane-Vives A, de Angel V, Papadopoulos A, et al. Short-term and long-term measures of cortisol in saliva and hair in atypical and non-atypical depression. Acta Psychiatr Scand. 2018;137(3):216–230. doi:10.1111/acps.12852
    1. Hartter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001;21(2):167–174. doi:10.1097/00004714-200104000-00008
    1. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. doi:10.1111/bdi.12609
    1. Thase ME. Antidepressant combinations: cutting edge psychopharmacology or passing fad? Curr Psychiatry Rep. 2013;15(10):403. doi:10.1007/s11920-013-0403-2
    1. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281–288. doi:10.1176/appi.ajp.2009.09020186
    1. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA. 2018;319(5):483–494. doi:10.1001/jama.2017.21903
    1. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi:10.1136/bmj.e7586
    1. Brensinger C, Herlim M, Bilker WB, Gur RC. A SAS® macro for visually displaying correlations between brain regions using fMRI data, SUGI. 2005. Available from: . Accessed September3, 2020.
    1. Tenke CE, Kayser J, Pechtel P, et al. Demonstrating test-retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response. Psychophysiology. 2017;54(1):34–50. doi:10.1111/psyp.12758
    1. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods. 2002;7(2):147–177. doi:10.1037/1082-989X.7.2.147
    1. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. SAS Institute, Incorporated; 1996.
    1. World medical A. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
    1. Dixon JR. The international conference on harmonization good clinical practice guideline. Qual Assur. 1998;6(2):65–74. doi:10.1080/105294199277860
    1. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi:10.1136/bmj.c332

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren